Skip to main content
FTH logo

Faeth Therapeutics, Inc.

FTHNASDAQHealthcareBiotechnology

$16.83Today:- (-)1Y +92.16%

As of Oct 26, 2026 close

Market cap
$94.98M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$7.45$42.14
Volume (live)
-
Avg. volume (3M)
429.85K

Faeth Therapeutics (FTH) Cash Flow Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), Faeth Therapeutics used $20.45M of cash in operating activities and spent $16.00K on capital expenditures. That left free cash flow of −$20.47M. It repurchased $4.00K of its own shares.

Faeth Therapeutics Cash Flow Statement Analysis

Values in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Faeth Therapeutics, Inc. (FTH) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Operating Activities
Net Income-21.09-30.16-34.10-48.59-36.79-20.10-16.74-13.04
Depreciation & Amortization0.120.551.351.350.690.210.070.04
Deferred Income Tax0.000.000.000.000.020.000.000.00
Stock Based Compensation1.273.144.455.815.661.490.001.19
Change in Working Capital-1.59-0.49-4.331.010.12-0.403.471.49
Change in Accounts Payable0.23-0.45-2.332.02-1.430.342.340.93
Change in Other Working Capital-1.83-0.04-2.001.191.54-0.731.130.56
Other Operating Activities0.832.290.601.190.081.094.630.35
Net Cash from Operating Activities-20.45-24.67-32.02-39.03-30.26-17.71-8.57-10.31
Investing Activities
Capital Expenditures-0.02-0.15-0.18-0.32-2.03-1.21-0.05-0.03
Acquisitions0.250.000.170.020.32-0.200.000.00
Purchases of Investments-25.16-44.60-21.15-46.87-183.670.000.000.00
Sales/Maturities of Investments44.6967.1859.5897.1242.260.000.000.00
Net Cash from Investing Activities19.7722.4438.4149.95-143.12-1.40-0.05-0.03
Financing Activities
Debt Repayment-0.65-0.81-0.76-0.63-0.260.538.070.75
Common Stock Issued0.010.030.050.34140.700.000.150.00
Common Stock Repurchased0.00-0.01-10.380.000.000.000.000.00
Other Financing Activities0.14-0.81-0.03-0.63-0.2634.930.000.00
Net Cash from Financing Activities-0.65-0.79-11.17-0.29163.9435.458.220.75
Summary
Effect of Forex Changes on Cash0.000.000.000.000.000.000.000.00
Net Change in Cash-1.33-3.02-4.7810.64-9.4416.35-0.40-9.59
Cash at Beginning of Period9.9913.0117.807.1616.600.250.6510.25
Cash at End of Period8.679.9913.0117.807.1616.600.250.65
Free Cash Flow-20.47-24.82-32.20-39.35-32.29-18.91-8.62-10.34

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Faeth Therapeutics Cash Flow

What is Faeth Therapeutics's free cash flow?

Faeth Therapeutics had negative free cash flow of $20.47M in fiscal 2025 (fiscal year ended Dec 31, 2025), operating cash flow of −$20.45M minus $16.00K of capital expenditures.

How much does Faeth Therapeutics spend on capital expenditures?

Faeth Therapeutics spent $16.00K on capital expenditures in fiscal 2025, compared with $146.00K a year earlier.

Does Faeth Therapeutics pay dividends or buy back shares?

Yes. In fiscal 2025 Faeth Therapeutics returned $4.00K in share buybacks to shareholders, according to its cash flow statement.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition